[go: up one dir, main page]

BR9909436A - Imunização de dna contra infecção de chlamydia - Google Patents

Imunização de dna contra infecção de chlamydia

Info

Publication number
BR9909436A
BR9909436A BR9909436-3A BR9909436A BR9909436A BR 9909436 A BR9909436 A BR 9909436A BR 9909436 A BR9909436 A BR 9909436A BR 9909436 A BR9909436 A BR 9909436A
Authority
BR
Brazil
Prior art keywords
host
immunization against
chlamydia infection
dna immunization
against chlamydia
Prior art date
Application number
BR9909436-3A
Other languages
English (en)
Inventor
Robert C Bruhnam
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Publication of BR9909436A publication Critical patent/BR9909436A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"IMUNIZAçãO DE DNA CONTRA INFECçãO DE CHLAMYDIA". ácido nucléico, inclusive DNA para imunização para gerar uma resposta imune protetora em um hospedeiro, inclusive humanos, em uma proteina de maior membrana externa de uma cepa de clamídias, contém de preferência uma seq³ência de nucleotídeos que codifica um fragmento que gera anticorpo que reagem especificamente com a MOMP e uma seq³ência de promotores acoplada operativamente a uma primeira seq³ência de nucleotídeos para expressão do fragmento da MOMP no hospedeiro. O vetor não-replicante pode ser formulado com um portador farmaceuticamente aceitável para administração in vivo no hospedeiro.
BR9909436-3A 1998-04-07 1999-04-07 Imunização de dna contra infecção de chlamydia BR9909436A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/055,765 US6344202B1 (en) 1996-07-12 1998-04-07 DNA immunization against chlaymdia infection
PCT/CA1999/000292 WO1999051745A2 (en) 1998-04-07 1999-04-07 Dna immunization against chlamydia infection

Publications (1)

Publication Number Publication Date
BR9909436A true BR9909436A (pt) 2004-06-29

Family

ID=22000011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909436-3A BR9909436A (pt) 1998-04-07 1999-04-07 Imunização de dna contra infecção de chlamydia

Country Status (9)

Country Link
US (4) US6344202B1 (pt)
EP (1) EP1068327A2 (pt)
JP (1) JP3881514B2 (pt)
AU (1) AU753539B2 (pt)
BR (1) BR9909436A (pt)
CA (1) CA2327434C (pt)
MX (1) MXPA00009830A (pt)
NZ (1) NZ507976A (pt)
WO (1) WO1999051745A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US20060073531A1 (en) * 1996-08-14 2006-04-06 Vanderbilt University Anti-chlamydial antibodies and uses thereof
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US7381421B2 (en) * 1999-12-13 2008-06-03 Lipoxen Technologies Limited Liposomes
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2010085896A1 (en) 2009-01-29 2010-08-05 British Columbia Cancer Agency Branch Compositions comprising chlamydia antigens
ES2788728T3 (es) 2010-05-28 2020-10-22 Spixia Biotechnology Ab Antígeno de la MOMP quimérica, método y uso
ES2900757T3 (es) 2015-02-10 2022-03-18 Ohio State Innovation Foundation Plataformas de células B activadas por clamidia y procedimientos de las mismas
JP7086000B2 (ja) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション 体液性親和性の加速に関する方法及び組成物
EP3600401A1 (en) * 2017-03-23 2020-02-05 Ohio State Innovation Foundation Recombinant chlamydia-activated b cell platforms and methods of use thereof
CN109897832B (zh) * 2019-03-29 2021-07-06 中牧实业股份有限公司 一株猪圆环病毒3型病毒毒株及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192033B1 (en) 1985-01-14 1996-09-25 Chiron Corporation Chlamydia major outer membrane protein
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
AU6718394A (en) 1993-05-13 1994-12-12 Connaught Laboratories Limited Hybrid picornaviruses expressing chlamydial epitopes
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US6235290B1 (en) * 1997-07-11 2001-05-22 University Of Manitoba DNA immunization against chlaymdia infection
US6696421B2 (en) * 1996-07-12 2004-02-24 University Of Manitoba DNA immunization against chlamydia infection
ATE312920T1 (de) 1996-07-12 2005-12-15 Dna immunisierung gegen chlamydia infektion
IL121115A (en) * 1997-06-19 2001-06-14 Savyon Diagnostics Ltd C. trachomatis specific peptides and their use in diagnostic assays

Also Published As

Publication number Publication date
AU753539B2 (en) 2002-10-24
JP3881514B2 (ja) 2007-02-14
AU3133699A (en) 1999-10-25
US6344202B1 (en) 2002-02-05
WO1999051745A3 (en) 1999-12-02
US7220423B2 (en) 2007-05-22
US6838085B2 (en) 2005-01-04
CA2327434C (en) 2009-09-01
EP1068327A2 (en) 2001-01-17
US7063853B1 (en) 2006-06-20
WO1999051745A2 (en) 1999-10-14
NZ507976A (en) 2002-12-20
US20050095254A1 (en) 2005-05-05
JP2002510493A (ja) 2002-04-09
CA2327434A1 (en) 1999-10-14
MXPA00009830A (es) 2003-07-14
US20020142001A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
BR9909436A (pt) Imunização de dna contra infecção de chlamydia
HUP9902310A2 (hu) Komplementer adenovírus-vektorrendszerek és sejtvonalak
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
BR9809304A (pt) "formulações de proteìna c ativada"
WO2004076489A8 (en) Modified antibody
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
BR0213940A (pt) Análogos de lipoxina a4
DE69824234D1 (de) Menschliche-"CDR-grafted"-Antikörper gegen Gangliosid gm2
AR003407A1 (es) Procedimiento de clonacion de un acido nucleico que codifica una proteina con actividad de delta-5,7-esterol, delta-7-reductasa, procedimiento de preparacion de la proteina, procemiento de reduccion in vitro de un esterol insaturado, procedimiento de produccion de pregnenolona, cepa de levadura transformada y metodo de diagnostico in vitro para la deteccion de la deficiencia de delta-5, 7-esterol, delta-7-reductasa
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
BR9904475A (pt) Molécula tipo anticorpo anti-fas, humanizada, agente para a profilaxia e/ou tratamento de condições envolvendo uma anormalidade no sistema ligando fas/fas, uso de um anticorpo, dna, vetor de dna recombinante, célula hospedeira, processo para produzir um anticorpo anti-pas, cepa transformante de e.coli, e, polipeptìdeo.
BR0016129A (pt) Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto
NZ526879A (en) Genes and proteins, and their use
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
DE60332425D1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
BR9803296A (pt) Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma.
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
Rosa-Fraile et al. Identification of a peptide from mammal albumins responsible for enhanced pigment production by group B streptococci
ES2169995B1 (es) Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]